AvenCell key facts
as of Oct 2026- Developer of T cell-based immunotherapies intended to support cancer treatment.
- AvenCell is valued at approximately $227.0M as of Oct 2026 (last reported valuation).
- It has raised $192.4M; the latest was Early Stage VC ($14.6M) in Sep 2025.
- Notable investors include F-Prime Capital, Eight Roads, Novo Holdings, NYBC Ventures, Blackstone Life Sciences — 10 tracked in total.
- Status: Privately Held (backing).
AvenCell's last reported valuation, Oct 2024. Nothing priced has surfaced since.
- ·Watch AvenCell: the Monday email on marks, rounds and moves
AvenCell funding rounds
No funding rounds for AvenCell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
AvenCell valuation
AvenCell's last reported valuation was $227 million in Oct 2024. No priced round, secondary trade or fund mark has surfaced since.
AvenCell investors
10 investors are on record for AvenCell, including F-Prime Capital, Eight Roads, Novo Holdings and NYBC Ventures.
About AvenCell
Developer of T cell-based immunotherapies intended to support cancer treatment. The company focuses on building chimeric antigen receptor T cells for precise targeting of cancer antigens to overcome the limitations of current-generation CAR-T cell therapies with an improved therapeutic window and substantially expand the types of cancer treatable with adoptive cell therapy, including solid tumors, enabling clinical researchers to create a pipeline of autologous and allogeneic universal reprogrammable T cell products, focused initially on hard-to-treat cancers.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2021
- Employees
- 66
- Website
- avencell.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.